Antidiabetic agents: Do they hit the right targets?
Yongting Zhao1
Xiaofang Zhang2
Haihai Liang3
Lihong Wang2
1.Department of Endocrinology, the First Affiliated Hospital of Jinan University, Guangzhou 510630, China;Department of Endocrinology, The Second Affiliated Hospital of Harbin Medical University, Harbin 150081, China2.Department of Endocrinology, the First Affiliated Hospital of Jinan University, Guangzhou 510630, China3.Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin 150081, China
摘要：Diabetes mellitus (DM) is a progressive metabolic disease characterized by chronic hyperglycemia and caused by different degree of pancreatic islet dysfunction and/or insulin resistance (IR). Long course DM can lead to a variety of macrovascular and microvascular complications which involve artery vessels, heart, kidney, retina, nervous system, etc. In recent years, DM has attracted more and more attention due to its high morbidity and mortality. In addition to achieve effective glycemic control, prevention of complications has also been considered a priority for type 2 diabetes mellitus (T2DM) management. Herein, we provide a comprehensive overview on the pharmacotherapeutics for T2DM and perspectives on the future directions of basic and translational research on anti-diabetic therapy and pharmatheutical development of new drugs. Keywords
机标关键词：agentsrightantidiabetictargetsthey
论文发表日期：2022-10-30
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：19( 225-243 )
英文信息